This Article Full Text Full Text (PDF) All Versions of this Article: 147/12/5584    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silva, D. Articles by Lopez, M. F. Search for Related Content PubMed PubMed Citation Articles by Silva, D. Articles by Lopez, M. F.

Igf2 Deficiency Results in Delayed Lung Development at the End of Gestation

Division of Endocrinology, Children’s Hospital, Harvard Medical School, Boston, Massachusetts 02115

Address all correspondence and requests for reprints to: Mary Frances Lopez, Ph.D., Division of Endocrinology, Children’s Hospital, 300 Longwood Avenue, Karp Research Building 04212, Boston, Massachusetts 02115. E-mail: mary.lopez{at}childrens.harvard.edu.

IGF-II is a polypeptide hormone with structural homology to insulin and IGF-I. IGF-II plays an important role in fetal growth as mice with targeted disruption of the IGF-II gene (Igf2) exhibit severe growth retardation. The role of IGFs in the fetal lung has been suggested by several studies, including those that have identified IGF mRNA expression, and that of their receptors and binding proteins in the lungs at different stages of development. In this study, we used mice carrying a null mutation of Igf2 (Igf2^–/– mice) to determine whether the absence of IGF-II had any effect in fetal lung maturation. Our results showed that the lungs of Igf2^–/– fetuses had thicker alveolar septae and poorly organized alveoli when compared with those of Igf2^+/+ on d 17.5 and 18.5 of gestation. These morphological alterations may be the result of exposure to lower levels of glucocorticoids because plasma corticosterone levels were significantly lower in Igf2^–/– mothers compared with wild-type controls. In support of this, fetuses from homozygous knockout matings, where mothers were treated with 15 µg/ml corticosterone, and Igf2^–/– fetuses obtained from heterozygous matings had similar lung histology to those of wild-type fetuses. Finally, we found that IGF-I and SP-B mRNA levels were up-regulated in the lungs of Igf2^–/– fetuses at the end of gestation. This study suggests that Igf2 plays an important role in the development of the fetal lung and may affect fetal lung maturation by regulating maternal factors, such as corticosterone levels, during pregnancy.

This article has been cited by other articles:

				E. Hsu and C. A. Feghali-Bostwick Insulin-Like Growth Factor-II Is Increased in Systemic Sclerosis-Associated Pulmonary Fibrosis and Contributes to the Fibrotic Process via Jun N-Terminal Kinase- and Phosphatidylinositol-3 Kinase-Dependent Pathways Am. J. Pathol., June 1, 2008; 172(6): 1580 - 1590. [Abstract] [Full Text] [PDF]

				K. E. Govoni, J. E. Wergedal, L. Florin, P. Angel, D. J. Baylink, and S. Mohan Conditional Deletion of Insulin-Like Growth Factor-I in Collagen Type 1{alpha}2-Expressing Cells Results in Postnatal Lethality and a Dramatic Reduction in Bone Accretion Endocrinology, December 1, 2007; 148(12): 5706 - 5715. [Abstract] [Full Text] [PDF]